News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
730,125 Results
Type
Article (47178)
Company Profile (352)
Press Release (682595)
Section
Business (213876)
Career Advice (2279)
Deals (37292)
Drug Delivery (111)
Drug Development (85147)
Employer Resources (174)
FDA (16813)
Job Trends (15780)
News (363035)
Policy (34866)
Tag
Academia (2691)
Alliances (52331)
Alzheimer's disease (1327)
Approvals (16761)
Artificial intelligence (184)
Bankruptcy (373)
Best Places to Work (11992)
Biotechnology (223)
Breast cancer (209)
Cancer (1594)
Cardiovascular disease (136)
Career advice (1896)
CAR-T (118)
Cell therapy (336)
Clinical research (68208)
Collaboration (610)
Compensation (317)
COVID-19 (2685)
C-suite (138)
Data (1497)
Diabetes (203)
Diagnostics (6387)
Earnings (87484)
Employer resources (153)
Events (116647)
Executive appointments (508)
FDA (17607)
Funding (538)
Gene therapy (233)
GLP-1 (712)
Government (4621)
Healthcare (19506)
Infectious disease (2790)
Inflammatory bowel disease (123)
Interviews (351)
IPO (16913)
Job creations (4214)
Job search strategy (1630)
Layoffs (468)
Legal (8602)
Lung cancer (236)
Manufacturing (234)
Medical device (13539)
Medtech (13544)
Mergers & acquisitions (20636)
Metabolic disorders (555)
Neuroscience (1719)
NextGen: Class of 2025 (6900)
Non-profit (4746)
Northern California (1892)
Obesity (320)
Opinion (236)
Patents (141)
People (59867)
Phase I (21215)
Phase II (29926)
Phase III (22428)
Pipeline (627)
Postmarket research (2806)
Preclinical (8986)
Radiopharmaceuticals (254)
Rare diseases (314)
Real estate (6434)
Regulatory (23300)
Research institute (2438)
Resumes & cover letters (384)
Southern California (1630)
Startups (3822)
United States (17085)
Vaccines (625)
Weight loss (243)
Date
Today (176)
Last 7 days (422)
Last 30 days (2000)
Last 365 days (35988)
2025 (1869)
2024 (36439)
2023 (41229)
2022 (52441)
2021 (57069)
2020 (55701)
2019 (48654)
2018 (36785)
2017 (33974)
2016 (33771)
2015 (39622)
2014 (33577)
2013 (28791)
2012 (30913)
2011 (31627)
2010 (29938)
Location
Africa (834)
Arizona (213)
Asia (41807)
Australia (6703)
California (4316)
Canada (1575)
China (378)
Colorado (197)
Connecticut (210)
Europe (90033)
Florida (616)
Georgia (149)
Illinois (437)
Indiana (255)
Maryland (708)
Massachusetts (3379)
Michigan (188)
Minnesota (323)
New Jersey (1215)
New York (1219)
North Carolina (842)
Northern California (1892)
Ohio (159)
Pennsylvania (1009)
South America (1254)
Southern California (1630)
Texas (636)
Utah (124)
Washington State (438)
730,125 Results for "mt pharma america inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Mitsubishi Tanabe Pharma America Presents Final Results from the Global, Phase 3b MT-1186-A02 Post-marketing Study of RADICAVA® (edaravone) in ALS
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of final results from the global, multi-center, double-blind, Phase 3b MT-1186-A02 study of oral edaravone in amyotrophic lateral sclerosis (ALS).
June 17, 2024
·
7 min read
Pharm Country
Mitsubishi Tanabe Pharma America, Inc. (MTPA) Stands with the ALS Community
Mitsubishi Tanabe Pharma America, Inc. is aware of recent external challenges facing the amyotrophic lateral sclerosis treatment landscape.
May 23, 2024
·
6 min read
Pharm Country
Mitsubishi Tanabe Pharma America Celebrates Second Anniversary of RADICAVA ORS® (edaravone) Launch in the U.S.
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the two-year launch anniversary of RADICAVA ORS ® (edaravone) in the U.S.
June 17, 2024
·
10 min read
Pharm Country
Mitsubishi Tanabe Pharma America to Present Latest Parkinson’s Disease Research at the 10th Congress of the European Academy of Neurology
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced three presentations on investigational ND0612 in Parkinson’s disease (PD) will be shared at the 10th Congress of the European Academy of Neurology (EAN), being held in Helsinki, Finland, June 29 – July 2.
June 28, 2024
·
3 min read
Pharm Country
Mitsubishi Tanabe Pharma America Presents New Results of RADICAVA® (edaravone) for People Living with ALS at the European Network to Cure ALS (ENCALS) Meeting 2024
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced results from two studies of RADICAVA® (edaravone) for amyotrophic lateral sclerosis (ALS) at the European Network to Cure Amyotrophic Lateral Sclerosis (ENCALS) 2024 meeting.
June 17, 2024
·
8 min read
Pharm Country
Mitsubishi Tanabe Pharma America Celebrates Eight-Year Anniversary in the U.S.
Mitsubishi Tanabe Pharma America, Inc. is celebrating its eight-year anniversary of being established in the United States.
April 29, 2024
·
10 min read
Pharm Country
Mitsubishi Tanabe Pharma America Announces Presentations at XXIX World Congress on Parkinson’s Disease and Related Disorders
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced two presentations on investigational ND0612 in Parkinson’s disease (PD) will be shared at the International Association of Parkinsonism and Related Disorders (IAPRD) XXIX World Congress on Parkinson’s Disease and Related Disorders, being held in Lisbon, Portugal.
May 16, 2024
·
3 min read
Press Releases
Mitsubishi Tanabe Pharma America to Present New ALS Research at MNDA’s 35th International Symposium on ALS/MND
December 3, 2024
·
9 min read
Press Releases
Mitsubishi Tanabe Pharma America to Present Data on Investigational ND0612 at the 2024 Annual Meeting of the Parkinson Study Group
December 4, 2024
·
3 min read
Pharm Country
Mitsubishi Tanabe Pharma America to Showcase Breadth of Neurodegenerative Research at 2024 American Academy of Neurology Annual Meeting
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced seven presentations will be shared at the American Academy of Neurology (AAN) 2024 Annual Meeting being held in Denver, Colo., Apr.13-18, 2024.
April 12, 2024
·
9 min read
1 of 73,013
Next
